Edgar Filing: IVERS-READ GILLIAN C - Form 4

IVERS-RE Form 4	AD GILLIAN	С							
March 04, 2	2013								
FOR		бр статес	SECU	DITIES	AND EV		E COMMISSIO	NT	PPROVAL
	UNIT	ED STATES		ashington				Number:	3235-0287
Check if no lo	this box			U				Expires:	January 31, 2005
subject	to SIAI	CHA	NGES IN		F Estimated	ated average			
Section Form 4				SECU	RITIES			burden hor response	•
Form 5 obligat	Incu	•					nge Act of 1934	,	
may co	ontinue. Section			•	•	mpany Act ny Act of 1	of 1935 or Sect	ion	
<i>See</i> Ins 1(b).	truction	50(II)	of the f	nvesunen	i Compa	IIY ACT OF I	1940		
(Print or Type	e Responses)								
	•								
	Address of Repor	e –		er Name an	d Ticker o	r Trading	5. Relationship Issuer	rson(s) to	
			Symbol Clovis	Oncology	, Inc. [C	LVS]			
(Last)	(First)	(Middle)		of Earliest T	_	-	(Ch	eck all applicabl	le)
				Day/Year)			Director X Officer (g		% Owner her (specify
	VIS ONCOLO 5 28TH STREE		03/01/2	2013			below)	below) See Remarks	ier (speerry
	(Street)		4. If Am	nendment, D	ate Origin	al	6. Individual or	Joint/Group Fili	ing(Check
				onth/Day/Yea	-		Applicable Line)	-	-
BOULDE	R, CO 80301							y One Reporting P y More than One R	
(City)	(State)	(Zip)	Tal	ble I - Non-	Derivative	e Securities A	Acquired, Disposed	of, or Beneficia	ally Owned
1.Title of		Date 2A. Deeme		3.	4. Securi		5. Amount of	6. Ownership	7. Nature of
Security (Instr. 3)	(Month/Day/Ye	ar) Execution any	Execution Date, if any		nAcquired Disposed		Securities Beneficially	Form: Direct (D) or Indirect	Indirect Beneficial
		(Month/Da	y/Year)		(Instr. 3, 4 and 5)		Owned	(I)	Ownership
						(A)	Following Reported	(Instr. 4)	(Instr. 4)
						(A) or	Transaction(s) (Instr. 3 and 4)		
				Code V	Amount	(D) Price	(IIISU: <i>3</i> and 4)		
Reminder: R	eport on a separate	e line for each cla	uss of sec	curities bene	ficially ow	ned directly	or indirectly.		
					inforı requi	mation cont red to resp	spond to the colle tained in this form ond unless the fo ntly valid OMB co	n are not orm	SEC 1474 (9-02)
					numb				
						sposed of, or convertible	Beneficially Owne	d	
1. Title of Derivative		Transaction Date onth/Day/Year)			4. Transact	5. Number tiorDerivative			7. Title and Amor Underlying Secur

Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of	8
erivative	Conversion	(Month/Day/Year)	Execution Date, if	Transactio	orDerivative	Expiration Date	Underlying Securities	D

Edgar Filing: IVERS-READ GILLIAN C - Form 4

Security (Instr. 3)	or Exercise Price of Derivative Security		any (Month/Day/Year)	Code (Instr. 8	6) A o (1 (1	-	uired (A) Disposed of tr. 3, 4,		(Instr. 3 and 4)		
				Code V	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	\$ 21.81	03/01/2013		A	,	75,000		<u>(1)</u>	03/01/2023	Common Stock	75,000
Denerting Augusta											

Reporting Owners

Reporting Owner Name / Addre	ess	Relationships							
1 8	Director	10% Owner	Officer	Other					
IVERS-READ GILLIAN C C/O CLOVIS ONCOLOGY, I 2525 28TH STREET, SUITE BOULDER, CO 80301			See Remarks						
Signatures									
/s/ Gillian C. Ivers-Read	03/01/2013								

**Signature of Reporting Date Person

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The option shall vest as to 25% of the shares on March 1, 2014 and the remainder shall vest in substantially equal installments over the 36 months immediately following such date.

Remarks:

Executive Vice President of Technical Operations and Chief Regulatory Officer

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

S (.